Pontoriero A, Critelli P, Zeppieri M, Bosurgi A, Guercio S, Caffo M, Angileri FF, Parisi S, Lavalle S, Pergolizzi S. Nano-drug delivery systems integrated with low radiation doses for enhanced therapeutic efficacy in cancer treatment. World J Clin Cases 2025; 13(10): 101719 [DOI: 10.12998/wjcc.v13.i10.101719]
Corresponding Author of This Article
Marco Zeppieri, MD, PhD, Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, Udine 33100, Italy. mark.zeppieri@asufc.sanita.fvg.it
Research Domain of This Article
Radiology, Nuclear Medicine & Medical Imaging
Article-Type of This Article
Scientometrics
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nano-drug delivery systems integrated with low radiation doses for enhanced therapeutic efficacy in cancer treatment
Antonio Pontoriero, Paola Critelli, Marco Zeppieri, Alberto Bosurgi, Stefania Guercio, Maria Caffo, Filippo Flavio Angileri, Silvana Parisi, Salvatore Lavalle, Stefano Pergolizzi
Antonio Pontoriero, Paola Critelli, Alberto Bosurgi, Silvana Parisi, Stefano Pergolizzi, Radiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina 98125, Italy
Marco Zeppieri, Department of Ophthalmology, University Hospital of Udine, Udine 33100, Italy
Stefania Guercio, Maria Caffo, Filippo Flavio Angileri, Neurosurgery Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, Messina, Italy, Messina 98125, Italy
Salvatore Lavalle, Department of Medicine and Surgery, University of Enna "Kore", Enna 94100, Italy
Author contributions: Pontoriero A and Critelli P wrote the outline, did the research, wrote the paper; Bosurgi A and Guercio S assisted in the research; Parisi S, Angileri FF assisted in the writing, editing, and making critical revisions, visualization and final approval of the manuscript; Pontoriero A and Pergolizzi S provided the final approval of the article; Zeppieri M assisted in the conception and design of the study, writing, outline, final approval of the version of the article to be published and completed the English and scientific editing.
Conflict-of-interest statement: All authors have no conflict of interest to declare.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marco Zeppieri, MD, PhD, Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, Udine 33100, Italy. mark.zeppieri@asufc.sanita.fvg.it
Received: September 24, 2024 Revised: November 11, 2024 Accepted: December 5, 2024 Published online: April 6, 2025 Processing time: 85 Days and 15.3 Hours
Abstract
BACKGROUND
Precision medicine is an emerging field that includes tumor-targeted delivery and tumor microenvironment. This review explores the synergistic potential of combining nano-drug delivery systems with low radiation doses to achieve optimized therapeutic outcomes, particularly in the context of cancer treatment. Nanoparticle-based drug carriers offer precise and targeted delivery, enhancing the therapeutic index of anticancer agents. The use of lower radiation doses has become a focus in radiation oncology to minimize off-target effects on healthy tissues in palliation treatment with high-target volume lesions.
AIM
To conduct a bibliometric review of nanomedicine and glioblastoma (GBM), all relevant studies from the last two decades were included.
METHODS
The search strategy comprised the keywords ”nanomedicine “and “glioblastoma” in the title and/or abstract. All English-language documents from 1 January 2000 to 31 December 2023 were considered for the analysis. R code (version 4.2.0) with R Studio (version 2022.12.0-353) and the Bibliometrix package (version 4.0.1) were used for the analysis. A total of 680 documents were collected.
RESULTS
We analyzed the bibliometric features of nanomedicine in glioma. With the limitations of the research, our analysis aims to highlight the increasing interest of researchers in the precision medicine field in GBM treatment and lead us to suggest further studies focusing on the association between nanomedicine and radiotherapy.
CONCLUSION
Due to the poor prognosis associated with GBM, new therapeutic approaches are necessary. There is an increasing interest in precision medicine, which includes nanomedicine and radiotherapy, for GBM treatment. This integration enhances the efficacy of targeted treatments and provides a promising avenue for reducing adverse effects, signifying a notable advancement in precision oncology.
Core Tip: Glioblastoma is a highly aggressive brain cancer, which main treatment consists of surgical resection or biopsy followed by radiotherapy and chemotherapy (STUPP protocol). Precision medicine is an emerging field that includes tumor-targeted delivery and tumor microenvironment. The integration of nano drug delivery systems with low radiation doses may offer a promising avenue for maximizing therapeutic efficacy and minimizing systemic toxicity.
